# What happens when you stop a GLP-1 medication

Updated 24 August 2026 · Written by the Penwise team

Stopping is not the mirror image of starting. The drug clears over several weeks, so nothing dramatic happens on the day of the last injection, and the change arrives gradually enough that people often misread it. The trials that deliberately withdrew treatment are unusually clear about what follows, and knowing the shape of it in advance is the difference between a planned stop and a confusing one.

## The drug does not leave when you stop taking it

Clearance follows the half-life, and for these drugs the half-life is long. Roughly five half-lives is the point at which a drug is considered effectively gone.

| Medication | Half-life | Effectively cleared after | Down to about half after |
| --- | --- | --- | --- |
| Semaglutide (Ozempic, Wegovy) | About 7 days | About 5 weeks | 1 week |
| Tirzepatide (Mounjaro, Zepbound) | About 5 days | About 25 days | 5 days |
| Retatrutide | About 6 days | About 30 days | 6 days |
| Liraglutide (Saxenda, Victoza) | About 13 hours | About 3 days | Same day |

Population figures. The point is the order of magnitude: weeks for the weekly drugs, days for the daily one.

The practical consequence is that the week after your last weekly shot feels essentially normal, because you still have most of a therapeutic level in you. Week two is lower. By week four on tirzepatide, or week five on semaglutide, there is effectively nothing left. That gradient is why people describe appetite creeping back rather than switching back on. The full curves are in the [semaglutide](https://penwiseapp.com/en/guides/how-long-does-ozempic-stay-in-your-system) and [tirzepatide](https://penwiseapp.com/en/guides/how-long-does-mounjaro-stay-in-your-system) decay tables.

Liraglutide is the exception. At a half-life of about 13 hours it is gone in days, which is why a missed dose on Saxenda is felt almost immediately and stopping it is a much sharper transition.

## What the withdrawal trials found

Two trials stopped the drug on purpose and followed what happened, which is far better evidence than anecdote.

- **Two thirds**: Of lost weight regained within a year of stopping semaglutide, in the STEP-1 extension
- **14%**: Weight regained over 52 weeks after switching from tirzepatide to placebo in SURMOUNT-4
- **5.5%**: Further weight lost over the same period by those who continued tirzepatide

The honest reading of both is that these drugs treat a condition rather than curing it, in the way blood-pressure medication does. Stopping removes the treatment effect, and for most people the underlying appetite regulation returns to roughly where it was. That is a statement about averages, and averages contain people who kept most of the loss and people who regained faster than the mean.

> Regain is not evidence of personal failure, and framing it that way is both wrong and unhelpful. It is the expected pharmacology of withdrawing a treatment that works while it is present.

## What actually comes back, and in what order

1. **Gastric emptying normalises first.** Meals start to feel less filling, and portions that were plenty become merely adequate.
2. **[Food noise](https://penwiseapp.com/en/guides/what-is-food-noise) returns.** For many people this is the most noticeable change and the one they miss most, because its absence was the part that made everything else easy.
3. **Hunger between meals returns.** Snacking cues that had been quiet for months come back.
4. **Weight follows.** Usually later than the appetite changes, which is why the scale is a lagging indicator of what is happening.

The gap between the appetite changing and the weight moving is where a record earns its keep. If you know that your intake started drifting in week three and the scale only responded in week six, you understand your own pattern. Without notes it reads as the weight coming back for no reason.

## Planned stopping versus a gap you did not choose

These are different situations that get discussed as one.

- **A supply gap**: Short interruptions are common and usually recoverable. If the gap is short enough that a meaningful level remains, restarting at the same dose is often possible, but it is a prescriber decision and it depends on how long the gap ran.
- **Stopping for side effects**: Often a dose question rather than a drug question. Dropping a rung frequently resolves what stopping entirely would also resolve, and keeps the benefit.
- **Stopping at a goal**: The situation the withdrawal trials modelled. Worth planning as a phase with its own monitoring, rather than treating as an end point where tracking stops.
- **Stopping for cost or access**: Increasingly the common reason, and the one where a complete record matters most, because it supports the case you will need to make to get back on.

A missed dose or two is a different question again, and it has its own page: [what a late dose actually costs](https://penwiseapp.com/en/guides/missed-glp-1-dose).

## Tapering

Reducing the dose in steps before stopping is common practice, and the evidence base for it is thin. There is no trial establishing that a taper prevents regain. What a taper does do is make the transition gradual and observable: you find out how appetite behaves at 5 mg before you find out how it behaves at zero, and that information is useful if the plan is to settle at a maintenance dose rather than to stop.

Maintenance dosing, where someone stays on the lowest dose that holds the result, is a real and increasingly common strategy. It is not stopping, and it does not carry the withdrawal-trial outcome, because the treatment is still present.

## What to have written down before you stop

Whatever the reason, the record you want afterwards has to exist before. Six things, all of which are trivial to keep and impossible to reconstruct.

- **The dose you were on and the date of your last injection.** Everything else is measured from that date.
- **Your weight at the stop, and your starting weight.** Percentage of loss retained is the number your prescriber will ask for.
- **What the dose ladder looked like on the way up.** If you restart, this is what determines whether re-titration is needed and how fast.
- **Which side effects you had and at which steps.** It is the difference between a fast and a cautious restart.
- **Weight weekly after stopping, not daily.** The trajectory is the signal and daily noise obscures it for the first month.
- **When appetite changed, in words.** The pattern of return is individual, and it is the only part of this nobody else can measure for you.

Penwise keeps all of that in one continuous history. Stopping is not a special mode: the estimated level keeps falling on the correct half-life after your last shot, so you can see exactly where you are in the clearance curve rather than guessing, and the record stays intact for whatever comes next.

## If you restart

Restarting after a long gap usually means re-titrating, because tolerance to the gastrointestinal effects fades along with the drug. Going straight back to the dose you finished on tends to reproduce the side effects of the original climb, which is why the standard advice is to step back up rather than resume. How far back depends on how long you were off and on the judgement of your prescriber, and your own record of the first climb is the most useful thing you can bring to that decision.

**A record that survives a pause** Clearance modelled on the real half-life, dose history kept intact, and everything on your phone. Free core tracker, no account.

## Common questions

**How long does it take for Ozempic to leave your system?**

Semaglutide has a half-life of about seven days, so it is effectively cleared after about five weeks. A week after your last injection you still have roughly half a therapeutic level, which is why nothing changes immediately.

**Will I regain the weight if I stop taking a GLP-1?**

The withdrawal trials found most people regain a substantial part of it. In the STEP-1 extension participants regained about two thirds of the lost weight within a year, and in SURMOUNT-4 those switched to placebo regained about 14% over 52 weeks while those who continued lost a further 5.5%.

**How soon after stopping does hunger come back?**

It follows the falling drug level rather than the last injection date. On the weekly drugs the first week feels close to normal, changes become noticeable in weeks two and three, and the full return arrives once the drug has effectively cleared at four to five weeks.

**Should I taper off a GLP-1 rather than stopping suddenly?**

Tapering is common practice and there is no trial evidence that it prevents regain. Its real value is that it makes the transition observable and it is the route to a maintenance dose, which is a different plan from stopping.

**Can I go back on the same dose if I restart?**

After a long gap, usually not. Tolerance to the gastrointestinal effects fades with the drug, so restarting at the finishing dose tends to reproduce the side effects of the original climb. Re-titration is the norm and the pace is a prescriber decision.

**Is stopping different on Saxenda?**

Yes, much sharper. Liraglutide has a half-life of about 13 hours and is effectively gone in about three days, so the transition happens over days rather than the four or five weeks the weekly drugs take.

## Sources

Every factual claim on this page traces to the product information a regulator publishes, or to a published trial. Links open on the site of whoever issued the document.

- [Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 extension)](https://doi.org/10.1111/dom.14725), Diabetes, Obesity and Metabolism, 2022
- [Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4)](https://doi.org/10.1001/jama.2023.24945), JAMA, 2024
- [Wegovy: EPAR product information](https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy), European Medicines Agency

Penwise is a tracking and education tool, not a medical device. Nothing on this page is medical advice, a diagnosis or a recommendation to start, stop or change a dose. Dosing decisions belong to you and your clinician. Ozempic, Wegovy, Rybelsus, Saxenda and Victoza are trademarks of Novo Nordisk; Mounjaro, Zepbound and Trulicity are trademarks of Eli Lilly. Penwise is not affiliated with, endorsed by or connected to either company.

## Keep reading

- [Missed a GLP-1 dose? What it actually costs you](https://penwiseapp.com/en/guides/missed-glp-1-dose): A day late on semaglutide is nothing. A day late on liraglutide is a real gap. Why the same question has a different answer for every product.
- [GLP-1 weight loss timeline: what happens month by month](https://penwiseapp.com/en/guides/glp-1-weight-loss-timeline): Month one is titration, not results. What the trials actually recorded at each stage, why the first six weeks mislead everybody, and how to read your own curve.
- [GLP-1 medications and mood: what the reviews found](https://penwiseapp.com/en/guides/glp-1-and-mood): Regulators reviewed the suicidality signal and did not find a causal link. What that does and does not settle, and the mood changes people genuinely report.
- [The GLP-1 weight loss plateau: what it is and what it is not](https://penwiseapp.com/en/guides/glp-1-weight-loss-plateau): Most reported plateaus are two weeks of noise on a trend that has not changed. Here is how to tell a real one from a scale reading, and what the log should show.